AML sample information
| Number . | Age, y . | Sex . | WHO diagnosis . | Cytogenetics . | % blasts . | Nrf2 mRNA (fold over CD34+) . | Nrf2 binding activity (fold over CD34+) . | NF-κB binding activity (fold over CD34+) . |
|---|---|---|---|---|---|---|---|---|
| AML#1 | 80 | M | AML without maturation | Normal | 95 | 10.04 | 6.00 | |
| AML#2 | 66 | F | Therapy-related myeloid neoplasm | Complex | 85 | 5.87 | 4.62 | |
| AML#3 | 61 | M | AML with myelodysplasia | Complex | 80 | 5.54 | 2.33 | 3.17 |
| AML#4 | 53 | M | Acute promyelocytic leukemia | t(15;17) | 95 | 0.68 | 1.16 | 1.26 |
| AML#5 | 77 | M | AML with myelodysplasia | Complex | 95 | 6.99 | 2.88 | 4.06 |
| AML#6 | 49 | M | AML with maturation | Normal | 80 | 6.24 | 3.26 | 4.65 |
| AML#7 | 39 | M | AML with maturation | Normal | 65* | 3.57 | 2.03 | 2.68 |
| AML#8 | 58 | M | Acute erythroid leukemia | Normal | 70 | 4.54 | 2.03 | 2.67 |
| AML#9 | 64 | M | AML with RUNX1-RUNX1T1 | t(8;21) | 85 | 0.88 | 1.09 | 1.98 |
| AML#10 | 92 | F | AML with myelodysplasia | Not available | 70 | 4.28 | 4.29 | |
| AML#11 | 57 | M | AML with myelodysplasia | Normal | 55 | 3.05 | 1.69 | 1.55 |
| AML#12 | 82 | F | AML with myelodysplasia | Deletion 13 | 85 | 2.96 | 2.10 | 1.99 |
| AML#13 | 46 | F | AML with maturation | +4,+8, t(9;22) | 70* | 4.97 | 2.27 | 3.05 |
| AML#14 | 40 | M | Acute promyelocytic leukemia | t(15;17) | 95 | 4.42 | 2.93 | 1.71 |
| AML#15 | 66 | F | AML without maturation | t(2;12) | 65* | 0.96 | 1.36 | 1.38 |
| AML#16 | 78 | M | AML with myelodysplasia | Not available | 85 | 1.13 | 0.93 | 0.89 |
| AML#17 | 57 | M | AML with minimal differentiation | Not available | 95 | 4.75 | 2.12 | 2.81 |
| AML#18 | 27 | M | AML with RUNX1-RUNX1T1 | t(8;21) | 60* | 6.42 | 3.86 | 5.64 |
| AML#19 | 28 | F | Acute myelomonocytic leukemia | Normal | 70 | 11.97 | 3.24 | 4.62 |
| AML#20 | 51 | F | AML with maturation | Normal | 75 | 6.85 | 3.56 | 5.15 |
| AML#21 | 77 | M | AML without maturation | Normal | 90 | 2.36 | 1.90 | |
| AML#22 | 85 | F | AML not otherwise specified | Not available | 75* | 4.31 | 2.32 | 3.14 |
| Number . | Age, y . | Sex . | WHO diagnosis . | Cytogenetics . | % blasts . | Nrf2 mRNA (fold over CD34+) . | Nrf2 binding activity (fold over CD34+) . | NF-κB binding activity (fold over CD34+) . |
|---|---|---|---|---|---|---|---|---|
| AML#1 | 80 | M | AML without maturation | Normal | 95 | 10.04 | 6.00 | |
| AML#2 | 66 | F | Therapy-related myeloid neoplasm | Complex | 85 | 5.87 | 4.62 | |
| AML#3 | 61 | M | AML with myelodysplasia | Complex | 80 | 5.54 | 2.33 | 3.17 |
| AML#4 | 53 | M | Acute promyelocytic leukemia | t(15;17) | 95 | 0.68 | 1.16 | 1.26 |
| AML#5 | 77 | M | AML with myelodysplasia | Complex | 95 | 6.99 | 2.88 | 4.06 |
| AML#6 | 49 | M | AML with maturation | Normal | 80 | 6.24 | 3.26 | 4.65 |
| AML#7 | 39 | M | AML with maturation | Normal | 65* | 3.57 | 2.03 | 2.68 |
| AML#8 | 58 | M | Acute erythroid leukemia | Normal | 70 | 4.54 | 2.03 | 2.67 |
| AML#9 | 64 | M | AML with RUNX1-RUNX1T1 | t(8;21) | 85 | 0.88 | 1.09 | 1.98 |
| AML#10 | 92 | F | AML with myelodysplasia | Not available | 70 | 4.28 | 4.29 | |
| AML#11 | 57 | M | AML with myelodysplasia | Normal | 55 | 3.05 | 1.69 | 1.55 |
| AML#12 | 82 | F | AML with myelodysplasia | Deletion 13 | 85 | 2.96 | 2.10 | 1.99 |
| AML#13 | 46 | F | AML with maturation | +4,+8, t(9;22) | 70* | 4.97 | 2.27 | 3.05 |
| AML#14 | 40 | M | Acute promyelocytic leukemia | t(15;17) | 95 | 4.42 | 2.93 | 1.71 |
| AML#15 | 66 | F | AML without maturation | t(2;12) | 65* | 0.96 | 1.36 | 1.38 |
| AML#16 | 78 | M | AML with myelodysplasia | Not available | 85 | 1.13 | 0.93 | 0.89 |
| AML#17 | 57 | M | AML with minimal differentiation | Not available | 95 | 4.75 | 2.12 | 2.81 |
| AML#18 | 27 | M | AML with RUNX1-RUNX1T1 | t(8;21) | 60* | 6.42 | 3.86 | 5.64 |
| AML#19 | 28 | F | Acute myelomonocytic leukemia | Normal | 70 | 11.97 | 3.24 | 4.62 |
| AML#20 | 51 | F | AML with maturation | Normal | 75 | 6.85 | 3.56 | 5.15 |
| AML#21 | 77 | M | AML without maturation | Normal | 90 | 2.36 | 1.90 | |
| AML#22 | 85 | F | AML not otherwise specified | Not available | 75* | 4.31 | 2.32 | 3.14 |
This table defines the nature of the AML disease, including WHO diagnosis and cytogenetics. Percent blast denotes the percentage of AML blasts after purification with the use of density gradient centrifugation and in some instances CD34+ positive selection. NF-κB and Nrf2 binding is indicated as a fold increase above levels from CD34+ cells. Nrf2 mRNA status indicates a marked difference in the levels of Nrf2 mRNA in AML samples compared with CD34+ control cells, as shown in Figure 1D.
AML indicates acute myeloid leukemia; Nrf2, NF-E2–related factor 2; and WHO, World Health Organization.
Samples that have been CD34+ positive selected.